Last Updated:
Suraksha Diagnostic IPO: It might be opened on November 29 and closed on December 3. The value band of the IPO has been fastened within the vary of Rs 420 to Rs 441 apiece.
Suraksha Diagnostic IPO.
Suraksha Diagnostic IPO GMP: The preliminary public providing of Suraksha Diagnostic Ltd goes to be opened on November 29. The Rs 846.25-crore IPO might be concluded on December 3. The value band of the IPO has been fastened within the vary of Rs 420 to Rs 441 apiece. However, the GMP stays zero as of now, exhibiting subdued curiosity within the gray market.
Suraksha Diagnostic IPO: Key Dates
The IPO might be opened on November 29 and closed on December 3. Its allotment will happen on December 4. Suraksha Diagnostic’s shares might be listing on each BSE and NSE on December 6.
Suraksha Diagnostic IPO GMP Today
According to market observers, unlisted shares of Suraksha Diagnostic Ltd had been buying and selling at Rs 441 apiece within the gray market on Thursday, which is similar as its challenge value. It means zero GMP on its unlisted shares within the gray market.
The GMP relies on market sentiments and retains altering. ‘Grey market premium’ signifies buyers’ readiness to pay greater than the difficulty value.
Suraksha Diagnostic IPO: Analysts’ Recommendations
Axis Capital in its IPO be aware saidd, “Suraksha Diagnostics is probably the most diversified when it comes to pathology and radiology among the many in contrast friends because it derived 53.30% of its income from pathology and 46.03% from radiology for FY24.”
The firm’s revenues from operations have grown at a CAGR of 20.83 per cent between FY2022-2024. For FY2024 the corporate reported revenues from operations at Rs 218.71 crore, with EBITDA margins of 33.66 per cent, PAT of Rs 23.13 crore. The firm’s internet debt to fairness ratio stood at 0.20x for FY2024, it added.
SBI Securities in its IPO stated, “At the higher value band of Rs 441, Suraksha Diagnostic is valued at FY24 P/E and EV/Sales a number of of 96.1x/5.1x respectively based mostly on its publish challenge capital. The firm is an built-in diagnostics supplier providing one-stop answer for pathology & radiology testing and medical session providers. As of FY24, Suraksha garnered a market share of almost 1.15%-1.30% in its core jap India market and goals to additional broaden its presence within the adjoining northeastern markets.”
The firm’s operations in core geography, in depth community and status will help in increasing its enterprise coupled with trade development which is predicted to develop from Rs 860-870 bn to Rs 1,275-1,375 bn by FY28, experiencing a CAGR of 10-12% between FY24-FY28, it added.
Another brokerage agency Bajaj Broking has granted a ‘subscribe for long run’ suggestion.
It stated, “If we annualise FY25 earnings to the post-IPO absolutely diluted fairness base, the asking value displays a P/E of 74.87. Based on FY24 earnings, the P/E stands at 99.32, indicating the IPO is absolutely priced. For the reported monetary intervals, whereas PAT margins will not be disclosed within the supply doc, the RoCE margins had been 23.11% (FY22), 9.05% (FY23), 21.46% (FY24), and 6.32% (Q1-FY25).”
Suraksha Diagnostic IPO: More Details
The IPO includes an entire offer-for-sale (OFS) of 19,189,330 fairness shares value Rs 846.25 crore (on the higher value band). All proceeds from the IPO will go to the promoting shareholders — promoters (Somnath Chatterjee, Ritu Mittal, and Satish Kumar Verma) and buyers (OrbiMed Asia II Mauritius Ltd, Munna Lal Kejriwal, and Santosh Kumar Kejriwal).
The value band of the Suraksha Diagnostic IPO has been set at Rs 420 to Rs 441 per share. The minimal lot dimension for an software is 34 shares. The minimal quantity of funding required by retail buyers is Rs 14,994. The minimal lot dimension funding for small NII is 14 tons (476 shares), amounting to Rs 209,916, and for giant NII, it’s 67 tons (2,278 shares), amounting to Rs 10,04,598.
At the higher finish of the worth band, the corporate’s market valuation stands at roughly Rs 2,300 crore.
ICICI Securities Limited, Nuvama Wealth Management Limited and SBI Capital Markets Limited are the e book operating lead managers of the Suraksha Diagnostic IPO, whereas Kfin Technologies Limited is the registrar for the difficulty.
